Skip to content
Search

Latest Stories

New NHS ADHD Taskforce to partner with ICBs, PCS, Clinical Teams

New NHS ADHD Taskforce to partner with ICBs, PCS, Clinical Teams

Post-covid the NHS received an astounding 4.3 million page views related to ADHD

A new Attention-Deficit-Hyperactive disorder (ADHD) taskforce has been launched by National Health Services England (NHSE) to counter the challenges faced by many suffering from the neurodevelopmental condition.


The ADHD taskforce aligns with the NHS Long Term Plan's vision to revolutionise mental health services, with a specific emphasis on bolstering community-based care and reducing reliance on inpatient services.

The NHS has partnered with the government to tackle the escalating demands including increasing funding, improving system efficiency, altering the service provision model, and clinical prioritisation by bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to help provide a joined-up approach in response to concerns around rising demand.

Over the past two decades, there has been a significant expansion in the acknowledgement and successful medical interventions for ADHD, leading to a steady rise in clinical requests throughout the UK.

However, the growing issue of prolonged waiting times for ADHD treatment has persisted without significant intervention, mainly due to the absence of defined targets for these wait times and the lack of regularly collected nationwide data.

This deficiency is primarily attributed to the absence of established targets for ADHD, unlike those in place for conditions like autism spectrum disorder.

Health leaders revealed that the taskforce's inception follows an exhaustive assessment of ADHD service provision and an analysis of the factors contributing to the surge in demand.

Initial findings highlighted overarching societal challenges such as capacity constraints, medication supply issues, service disparities, and inadequate data reliability, which the expert group will delve into further.

According to the National Institute for Health and Care Excellence (NICE), the prevalence of ADHD in adults is estimated at 3 per cent to 4 per cent, with a male-to-female ratio of approximately 3:1.

This compounds with the statistical data outcomes highlighted by NHSE.

According to it, ADHD emerged as the second most searched health condition on the NHS website in 2023, following Covid-19, with a staggering 4.3 million page views throughout the year.

The new initiative aims to engage with a spectrum of stakeholders, including patients, service providers, Integrated Care Boards (ICBs), primary care services, local authorities, schools, educational institutions, and clinical teams and compile insights that will be published by the end of the year.

This is in addition to NHSE's commitment to developing a national ADHD data improvement plan, conducting in-depth analyses of provider and commissioning landscapes, and showcasing innovative service delivery models from local health systems.

NHS chief executive Amanda Pritchard stressed the urgency of addressing the gaps in ADHD services, emphasising that "NHS staff across the country are working hard to ensure all patients requiring assessments and further support from ADHD services are seen as promptly as possible."

She underscored the complexity of the taskforce's mandate and emphasised the need for collaboration with partners and experts to drive tangible improvements.

Steve Russell, chief delivery officer at NHS England, highlighted ongoing efforts to enhance data collection and streamline pathways for ADHD patients, leveraging insights from the initial review.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less